Welcome to our dedicated page for Wuxi Apptec news (Ticker: WUXAY), a resource for investors and traders seeking the latest updates and insights on Wuxi Apptec stock.
WuXi AppTec Co., Ltd. (WUXAY) news covers developments at a global pharmaceutical and life sciences technology platform company that provides integrated CRDMO (Contract Research, Development and Manufacturing Organization) services. Company announcements highlight how WuXi AppTec supports drug discovery, development and manufacturing for thousands of customers across Asia, Europe and North America.
On this page, readers can follow news about WuXi AppTec’s segment performance in WuXi Chemistry, WuXi Testing and WuXi Biology, along with updates on its small molecule and TIDES (oligonucleotide and peptide) pipelines, backlog growth and capacity expansion. The company frequently reports revenue and profit trends for continuing operations, adjusted non-IFRS metrics, and backlog figures prepared under IFRSs and China Accounting Standards.
WuXi AppTec’s news flow also features regulatory and quality milestones, such as FDA inspections at its Changzhou and Taixing API manufacturing sites completed with no observations, as well as recognition for its facilities like the Nantong site’s Architizer A+Award. ESG-related announcements are another recurring theme, including inclusion in the FTSE4Good Index Series, MSCI ESG ratings, DJSI membership and validation of emissions reduction targets by the Science Based Targets initiative (SBTi).
Investors and observers can also track capital allocation actions such as cash dividends, interim and special dividends, A-share repurchase and cancellation programs, and H-share acquisition activities under share award and trust schemes. Bookmark this page to monitor WuXi AppTec’s official press releases, financial updates, ESG milestones and operational achievements that shape the outlook for the underlying business represented by WUXAY.
WuXi AppTec reported Q3 2024 revenue of RMB10,461 million, up 14.6% YoY excluding COVID-19 commercial projects. For the first three quarters, revenue reached RMB27,702 million, growing 4.6% YoY excluding COVID-19 projects. Net profit attributable to owners was RMB6,533 million with diluted EPS of RMB2.24. The company's backlog grew 35.2% YoY to RMB43.82 billion. Operating cash flow increased 10.4% YoY with free cash flow of RMB5.56 billion. The company added over 800 new customers while maintaining 6,000+ active customers. Revenue from top 20 pharmaceutical companies grew 23.1% YoY to RMB11.22 billion excluding COVID-19 projects.
WuXi AppTec reported financial results for the first half of 2024. Revenue for Q2 2024 was RMB9,259 million, up 16.0% QoQ. Adjusted non-IFRS net profit increased by 28.5% QoQ to RMB4,372 million. For H1 2024, revenue excluding COVID-19 projects was RMB17,241 million, down 0.7% YoY, with an adjusted gross profit margin of 39.8%. The net profit attributable to shareholders was RMB4,240 million. Operating cash flow grew 48.3% YoY. The company added over 500 new customers and achieved a backlog of RMB43.10 billion, up 33.2% YoY. WuXi Chemistry recorded H1 revenue of RMB12.21 billion, growing 2.1% YoY. TIDES business revenue grew 57.2% YoY. WuXi Testing saw a 5.4% decline in lab testing revenue. WuXi ATU revenue dropped 19.4% YoY due to U.S. legislation impacts. For the full year, WuXi AppTec aims for revenue between RMB38.3-40.5 billion and free cash flow of RMB4-5 billion.
WuXi AppTec reported a 5.8% increase in revenue year-over-year, reaching
FAQ
What is the current stock price of Wuxi Apptec (WUXAY)?
What is the market cap of Wuxi Apptec (WUXAY)?
